低剂量达沙替尼50毫克/天与标准剂量达沙替尼100毫克/天作为慢性期慢性髓性白血病一线治疗的比较:倾向性评分分析
该研究纳入233例新诊断慢性期慢性髓性白血病患者,分别接受低剂量达沙替尼50毫克/天(83例)或标准剂量100毫克/天(150例),经1:1倾向性评分匹配后每组77例。中位随访60个月,低剂量组3年MR4和MR4.5累积发生率更高,4年无失败生存率更高,胸腔积液发生率更低。
要点
- 低剂量达沙替尼50毫克/天与标准剂量100毫克/天相比,3年MMR率分别为92%和84%(p=.23),无显著差异。
- 低剂量组3年MR4累积发生率为77%,标准剂量组为66%(p=.04);MR4.5分别为77%和62%(p=.02)。
- 低剂量组4年无失败生存率为89%,标准剂量组为77%(p=.04);任何级别胸腔积液发生率分别为5%和21%。
核心结论
- 低剂量达沙替尼50毫克/天至少与100毫克/天同样有效,且安全性特征和药物暴露更优。
研究设计与样本
- 研究分析了233例新诊断慢性期慢性髓性白血病患者,其中低剂量达沙替尼50毫克/天组83例,标准剂量100毫克/天组150例。
- 采用1:1倾向性评分匹配,每组各识别出77例基线无显著差异的患者。
- 低剂量组中按欧洲白血病网2013标准判定为次优反应的患者可选择将剂量增加至100毫克/天。
- 总体中位随访时间为60个月。
主要发现
- 3年主要分子学缓解率在低剂量组为92%,标准剂量组为84%(p=.23)。
- 3年MR4累积发生率低剂量组为77%,标准剂量组为66%(p=.04);MR4.5累积发生率分别为77%和62%(p=.02)。
- 4年无失败生存率低剂量组为89%,标准剂量组为77%(p=.04);4年无事件生存率分别为95%和92%(p=.06);4年总生存率分别为97%和96%(p=.78)。
- 任何级别胸腔积液发生率在达沙替尼50毫克/天组为5%,在100毫克/天组为21%。
关键数值与推荐
- 3年主要分子学缓解率:低剂量组92% vs 标准剂量组84%(p=.23)。
- 3年MR4累积发生率:低剂量组77% vs 标准剂量组66%(p=.04);MR4.5:低剂量组77% vs 标准剂量组62%(p=.02)。
- 4年无失败生存率:低剂量组89% vs 标准剂量组77%(p=.04);无事件生存率:低剂量组95% vs 标准剂量组92%(p=.06);总生存率:低剂量组97% vs 标准剂量组96%(p=.78)。
- 任何级别胸腔积液发生率:达沙替尼50毫克/天组5% vs 100毫克/天组21%。
临床怎么用
- 低剂量达沙替尼50毫克/天组中,按欧洲白血病网2013标准判定为次优反应的患者可选择将剂量增加至100毫克/天。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Low-dose dasatinib is safe and effective in patients with chronic myeloid leukemia in chronic phase (CML-CP). No randomized trials have compared the outcome with standard-dose dasatinib. This study aims to compare the outcome of patients with CML-CP treated with frontline dasatinib 50 versus 100 mg/day. We analyzed 233 patients with newly diagnosed CML-CP treated with low-dose dasatinib (N = 83) or standard-dose dasatinib (N = 150). Propensity score analysis with 1:1 matching was performed and identified 77 patients in each cohort without significant baseline differences. Response rates were reported as the cumulative incidences of complete cytogenetic response, major molecular response (MMR), molecular response (MR)4, and MR4.5. Failure-free survival (FFS), event-free survival (EFS), transformation-free survival (TFS), and overall survival (OS) were also compared. Patients on low-dose dasatinib with suboptimal response by European LeukemiaNet (ELN) 2013 criteria had the option to increase the dose to 100 mg/day. The overall median follow-up time was 60 months. The 3-year MMR rates were 92% and 84% for low-dose and standard-dose dasatinib, respectively (p = .23). Dasatinib 50 mg/day induced higher cumulative incidence of MR4 (77% vs. 66%; p = .04) and MR4.5 (77% vs. 62%; p = .02) at 3 years. The 4-year FFS, EFS and OS rates were 89% versus 77% (p = .04), 95% versus 92% (p = .06), and 97% versus 96% (p = .78) with low-dose and standard-dose dasatinib, respectively. The rate of any grade pleural effusion was 5% with dasatinib 50 mg/day compared to 21% with 100 mg/day. Dasatinib 50 mg/day is at least as effective as 100 mg/day with a better safety profile and drug exposure.
引用
- Jabbour E, Sasaki K, Haddad FG, et al. Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol. 2022. PMID: 36054032. doi:10.1002/ajh.26689
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。